{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:12:56Z","timestamp":1791112376056,"version":"4.1.0"},"reference-count":14,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7,1]]},"abstract":"<jats:p>Tuberous sclerosis complex (TSC) is a genetic disorder characterized by mammalian target of rapamycin (mTOR) activation and growth of benign tumors. Some TSC lesions, such as cardiac rhabdomyomas and cortical tubers in the brain, occur in fetuses, and some, such as renal angiomyolipomas (AMLs) and skin angiofibromas, develop over years. Recently, the mTOR inhibitor everolimus was shown to be effective in the treatment of subependymal giant cell astrocytomas (a brain tumor) and renal AMLs (kidney tumors) in TSC patients. We present monozygotic twin sisters affected with TSC. Since age 4 years, 1 of the sisters has been treated with everolimus; the other sister received no mTOR inhibitor treatment. After 24-month follow-up, everolimus treatment resulted in a significant brain tumor volume decrease in the treated twin. This child presents no facial angiofibroma, and no renal AMLs. The brain tumor in the nontreated sister is stable in size, but in the meantime, she has developed significant facial angiofibroma and renal AMLs. This observation indicates that early mTOR inhibition in TSC patients may prevent the development of TSC lesions and alter the natural history of the disease.<\/jats:p>","DOI":"10.1542\/peds.2012-3607","type":"journal-article","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T01:13:07Z","timestamp":1370308387000},"page":"e239-e242","source":"Crossref","is-referenced-by-count":41,"title":["Possible Prevention of Tuberous Sclerosis Complex Lesions"],"prefix":"10.1542","volume":"132","author":[{"given":"Katarzyna","family":"Kotulska","sequence":"first","affiliation":[{"name":"Departments of Science, and"},{"name":"Neurology and Epileptology, The Children\u2019s Memorial Health Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julita","family":"Borkowska","sequence":"additional","affiliation":[{"name":"Neurology and Epileptology, The Children\u2019s Memorial Health Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiusz","family":"Jozwiak","sequence":"additional","affiliation":[{"name":"Neurology and Epileptology, The Children\u2019s Memorial Health Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2013,7,1]]},"reference":[{"issue":"9639","key":"2021120900143982200_B1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis.","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"issue":"10","key":"2021120900143982200_B2","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1177\/088307380001501003","article-title":"Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients.","volume":"15","author":"J\u00f3zwiak","year":"2000","journal-title":"J Child Neurol"},{"issue":"1","key":"2021120900143982200_B3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/316951","article-title":"Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.","volume":"68","author":"Dabora","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"8","key":"2021120900143982200_B4","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0025-6196(12)61196-3","article-title":"Causes of death in patients with tuberous sclerosis.","volume":"66","author":"Shepherd","year":"1991","journal-title":"Mayo Clin Proc"},{"key":"2021120900143982200_B5"},{"issue":"5","key":"2021120900143982200_B6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1034\/j.1399-0004.2003.00073.x","article-title":"Discordant clinical manifestations in monozygotic twins with the identical mutation in the TSC2 gene.","volume":"63","author":"Martin","year":"2003","journal-title":"Clin Genet"},{"issue":"5","key":"2021120900143982200_B7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1212\/01.WNL.0000113745.58425.EF","article-title":"Monozygotic twins with tuberous sclerosis discordant for the severity of developmental deficits.","volume":"62","author":"Humphrey","year":"2004","journal-title":"Neurology"},{"issue":"12","key":"2021120900143982200_B8","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1177\/0883073807307093","article-title":"Intrafamilial phenotypic variability in tuberous sclerosis complex.","volume":"22","author":"Lyczkowski","year":"2007","journal-title":"J Child Neurol"},{"issue":"6","key":"2021120900143982200_B9","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1086\/302648","article-title":"Complete inactivation of the TSC2 gene leads to formation of hamartomas.","volume":"65","author":"Au","year":"1999","journal-title":"Am J Hum Genet"},{"issue":"23","key":"2021120900143982200_B10","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1093\/hmg\/ddr393","article-title":"Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex.","volume":"20","author":"Anderl","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"4","key":"2021120900143982200_B11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.","volume":"63","author":"Zeng","year":"2008","journal-title":"Ann Neurol"},{"issue":"14","key":"2021120900143982200_B12","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1093\/hmg\/dds156","article-title":"The differential effects of prenatal and\/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex.","volume":"21","author":"Way","year":"2012","journal-title":"Hum Mol Genet"},{"issue":"6","key":"2021120900143982200_B13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00467-011-1811-3","article-title":"Growth of kidney-transplanted pediatric patients treated with sirolimus.","volume":"26","author":"Gonz\u00e1lez","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"2021120900143982200_B14","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2217\/fon.12.146","article-title":"Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.","volume":"8","author":"J\u00f3zwiak","year":"2012","journal-title":"Future Oncol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/132\/1\/e239\/1102164\/peds_2012-3607.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/132\/1\/e239\/1102164\/peds_2012-3607.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T05:47:54Z","timestamp":1639028874000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/132\/1\/e239\/31380\/Possible-Prevention-of-Tuberous-Sclerosis-Complex"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,1]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,7,1]]},"published-print":{"date-parts":[[2013,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2012-3607","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,1]]}}}